How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    • Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about crisaborole

Anticipated marketing authorisation indication

2.1 On 30 January 2020, the Committee for Medicinal Products for Human Use adopted a positive opinion recommending the granting of a marketing authorisation for the medicinal product crisaborole (Staquis, Pfizer) for the treatment of 'mild to moderate atopic dermatitis in adults and paediatric patients from 2 years of age with ≤ 40% body surface area (BSA) affected'.

Dosage in the marketing authorisation

2.2 Crisaborole is a topical ointment that is applied as a thin layer twice daily to affected skin areas of up to 40% of the body's surface area. It can be used on all skin areas apart from the scalp for up to 4 weeks. Treatment should be stopped if signs or symptoms on treated areas persist after 3 treatment courses of 4 weeks, or worsen during treatment.

Price

2.3 The company has not confirmed the list price for crisaborole with the Department of Health and Social Care. The proposed list price is considered confidential by the company.